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CHAPTER 1: INTRODUCTION
1.1 The AID/APOBEC family
The AID and APOBEC family of proteins catalyze the deamination of cytosines to
uracils in single stranded DNA and/or RNA. They all share a conserved zinc binding
domain, His-X-Glu-X25-31-Pro-Cys-X2-4-Cys. (X is any amino acid). The zinc (Z)coordinating motif is important in cytosine deamination. They possess either one or two of
these domains (highlighted in Figure 1). Humans have seven APOBEC3 members.

Figure 1: Members of the AID/APOBEC family of enzymes in higher vertebrates.
The zinc-binding domain is highlighted.
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APOBEC1 was the first enzyme to be identified in this family of enzymes, which plays
an essential role in lipid metabolism [1, 2]. APOBEC1 introduces a premature translation
termination codon in the pre-mRNA of Apolipoprotein B100, producing a shorter version,
namely, Apolipoprotein B48. The two versions have differential activities regulating
lipoproteins in liver. Mammalian APOBEC1 acts on RNA, but as discovered by Harris et
al. in 2002, it can also act on single stranded DNA [3].
AID was the second member to be identified in this family by Muramatsu et al. in
1999 [4]. It deaminates cytosines in single stranded DNA [3, 5]. AID plays a remarkable
role in adaptive immunity in higher vertebrates. Specifically, AID is essential for antibody
diversification and for the genearation of high affinity antibodies. In B cell immunoglobulin
genes, AID introduced uracils are processed in different DNA repair and recombination
pathways leading to class switch recombination and somatic hypermutation [6, 7]. These
processes are essential in efficient immune defense against pathogens.

1.2 APOBEC3 sub-family
Over the past 100 million years, APOBEC enzymes have evolved as a protective
mechanism of immunity to prevent viruses and pathogens from infecting the organisms.
The ancestral zinc binding deaminase domain has duplicated several times in humans
within 150 kb in chromosome 22. This duplication encodes several APOBEC3 proteins [8].
The human APOBEC3 family consists of seven members, containing one or two zinc
binding deaminase domains, namely, APOBEC3A-APOBEC3H. Primates also have
multiple APOBEC3 genes that have undergone expansion and duplication, while rodents
have a single APOBEC3 gene in their genomes [9]. The importance of this expansion of
the APOBEC3 genes may be implicated in the protective function of restricting evolving
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endogenous and exogenous retroviruses or retroelements in these higher organisms.
More specifically, APOBEC3 enzymes are potent inhibitors of replication of exogenous
retroviruses such as HIV-1 [10] although with varying levels [11, 12].

Figure 2: The arrangement of the APOBEC3 genes in human chromosome 22.

1.3 Mouse APOBEC3 enzyme
In contrast to humans, mice have one APOBEC3 gene. It is located in
chromosome 15 which is syntenic to human chromosome 22 [13]. This gene encodes for
a double domain DNA cytosine deaminase. In contrast to human APOBEC3G, where only
the CTD is catalytically active, the NTD is catalytically active in mouse APOBEC3. The
NTD is thought to be necessary for encapsidation of this enzyme into retroviruses. It
shares ~33% sequence similarity with human APOBEC3G [14, 15]. Mouse APOBEC3 is a
powerful restrictor of vif-deficient HIV-1, and the efficiency of restriction is comparable to
that of the human APOBEC3G. Mouse APOBEC3 can introduce high levels of G to A
mutations in the HIV-1 genome; hence the mechanism of restriction is deaminase
dependent [16]. On the other hand, its ability to restrict murine retroviruses, such as MLV
is limited compared to human APOBEC3G [17]. In biochemical terms, purified mouse
APOBEC3 is capable of deaminating cytosine in short single stranded DNA, preferably
towards the 3’ end [16]. Mouse APOBEC3 is expressed widely in lymphoid tissue. Despite
the useful role played by mouse APOBEC3, it is not essential for the survival or
development of mice [18].
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1.4 Human APOBEC3 enzymes
APOBEC3A is a single domain DNA cytosine deaminase, which is implicated in its
potential for restricting a myriad of retroviruses including HIV-1 [19, 20]. APOBEC3A has
also has the potential to restrict certain DNA viruses such as HPV [21] and parvovirus
[22]. Overexpressed APOBEC3A is capable of translocating to the nucleus and inducing
genomic DNA damage [23]. However, Harris et al. suggested that endogenous
APOBEC3A is cytoplasmic and incapable of genomic DNA editing [24]. Recently, it was
also suggested that APOBEC3A can act as a foreign DNA restricting enzyme in
mammalian cells [25]. In addition to DNA cytosine deaminase activity, APOBEC3A is
efficient in deaminating 5-methylcytosines, suggesting a possible role in epigenetic gene
regulation [26, 27]. APOBEC3A is a myeloid specific enzyme and type-1 interferon can
increase its expression 10-1000 fold [19], consistent with its antiretroviral activity.
APOBEC3B contains two conserved zinc binding cytosine deaminase domains. Several
recent studies have shown that it is an enzymatic source of mutations in several human
cancers, including breast cancer [28, 29]. It is the only APOBEC3 enzyme with nuclear
localization [29]. Although there is no crystal or NMR structures available, APOBEC3B
has been studied extensively as it can be targeted by anticancer drugs. APOBEC3C
contains one zinc binding cytosine deaminase domain, and is implicated in HBV [30, 31]
and SIV [32] restriction. A high resolution crystal structure of full length APOBEC3C was
determined recently [33]. APOBEC3D, which was previously termed, APOBEC3DE is a
moderately potent HIV-1 inhibitor in T cells. In contrast, it is a potent inhibitor of Alu
retrotransposition. As discussed below, APOBEC3D evolved under positive selection with
loss of function mutations [34]. APOBEC3F contains two zinc binding domains. A high
resolution crystal structure of the catalytically active APOBEC3F CTD is available [35].

5

APOBEC3F is capable of restricting vif deficient HIV-1 but it is susceptible to vif mediated
degradation [36, 37]. Vif is a HIV-1 encoded viral accessory protein that binds APOBEC3
proteins and targets them for degradation, through ubiquitin proteasome pathway.
APOBEC3G is the most studied and well characterized member of the APOBEC3 family
of enzymes. The crystal structure of the catalytically active CTD of APOBEC3G was first
established by Holden et a.l in 2008 [38]. The protein was purified from E.coli as a GST
fusion. The NMR structure of the CTD of APOBEC3G was also published, but in a more
soluble mutant form (2K3A) [39]. Numerous studies show that APOBEC3G possess very
efficient HIV-1 restriction potential, but similar to APOBEC3F, it is susceptible to vifmediated degradation [40, 41].
The structures of the APOBEC3 deaminase domains provide insight into the
mechanisms and the activity of the APOBEC3 enzymes and the substrate specificity of
these proteins. APOBEC3 enzymes are emerging as targets of potential anti-cancer and
anti-retroviral drugs. Furthermore, the residues of APOBEC3 enzymes that are involved in
HIV-1 vif binding need to be studied. In addition, to study the mechanism underlying
retroviral restriction by APOBEC3 proteins and to understand their role in innate immunity,
high resolution crystal or NMR structures would be useful. Unfortunately, some of these
enzymes are insoluble and tend to precipitate in high concentrations as the molecules
tend to aggregate [42]. Up to now, several groups were able to obtain the structures of the
APOBEC3G CTD [39, 42], APOBEC3C [33], APOBEC3A [43] and C-terminal domain of
APOBEC3F [35]. APOBEC3H was the focus of my studies is described below.
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1.5 HIV-1 restriction by APOBEC3 proteins
To explain the mechanism of HIV-1 restriction by APOBEC3 enzymes,
APOBEC3G is taken as the example. Vif-deficient HIV-1 virus infects human CD4+ T
cells. APOBEC3G is expressed exclusively in the cytoplasm of these cells [41, 44]. To
restrict HIV-1 replication and infection, APOBEC3G is first packaged into the viral core
[41]. Once the virus particle infects a new target cell, APOBEC3G plays its role in viral
restriction. HIV-1 begins to reverse transcribe the RNA genome to the cDNA intermediate
which is the target for APOBEC3G [45]. The enzyme deaminates cytosines to uracils in
this minus strand cDNA, which leads to degradation of the product. On the other hand, the
uracil-rich cDNA undergoes synthesis of the second DNA strand (plus strand), generating
G to A hypermutations in the pro-viral genome, which is detrimental for the replication of
the virus [41, 45]. Virally encoded vif protein is capable of interacting with APOBEC3G
and targeting it to ubiquitin proteasome mediated degradation [40].
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Figure 3: Mechanism of retroviral restriction mediated by APOBEC3 enzyme.
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1.6 APOBEC3H enzymes
During host and pathogen protein interactions, evolution plays a key role in
domination of either the host or the pathogen. This phenomenon is observed in the
evolution of APOBEC3 proteins [46]. As APOBEC3 proteins are involved in restricting
retroviruses, the evolution of the viral proteins that counteract the action of APOBEC3 also
show strong positive selection [47]. At the same time, host defensive proteins, such as
APOBEC3 enzymes, have undergone multiple diversifications and duplications to better
counteract viral replication in cells. APOBEC3H evolved from ancestral genes at least 33
million years ago during primate evolution [48].
The human APOBEC3H gene is located downstream of APOBEC3G. It contains a
single zinc binding domain. The function of APOBEC3H is poorly characterized. The
presence of conserved a cytosine deaminase domain suggested that APOBEC3H might
play a role in genome defense. It shares much less amino acid sequence similarity to
other single domain cytosine deaminase, APOBEC3A (~29.6%) and APOBEC3C
(~34.6%). APOBEC3H mRNA was detected in peripheral blood mononucleated cells
(PBMC), testis, ovary and skin [48]. Also, the mRNA level of human APOBEC3H was
upregulated >22-fold upon stimulation with interferon in CD4+ T cells [49]. Primate
APOBEC3H consists of an evolutionarily distinct cytosine deaminase domain [9]. It is
considered as the most evolutionarily divergent APOBEC3 protein and evolved under
strong positive selection. Previously it was not identified as a retroviral restriction factor in
primates, but the position of the APOBEC3H gene proximal to APOBEC3G and the
possession of the conserved zinc binding deaminase domain, lead the researchers to
investigate its potential in innate immunity and for the retroviral restriction. Until the whole
genome sequencing project was completed, APOBEC3H was not identified as a cytidine
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deaminase [9, 13]. APOBEC3H of OWMs, such as macaques, possess strong restriction
activity against primate lentiviruses, for example, HIV-1 and SIV [48]. In contrast, the
protein expression of human APOBEC3H was poor in primate cells and shows much less
restriction ability of retroviruses compared to OWM APOBEC3H [48]. Of note, human
APOBEC3H was unable to restrict vif-deficient HIV-1 [48]. In contrast, feline APOBEC3H
is a potent inhibitor of HIV-1 and induced G to A mutations in HIV-1 genome [50]. Despite
the low levels of human APOBEC3H proteins detected in the transfected cells, mRNA
levels were comparable to the level detected in OWM. By successfully expressing OWM
and human APOBEC3H in bacteria, OhAinle M. et al. [51] demonstrated that both proteins
show DNA cytosine deaminase activity. Using a bacterial rifampicin resistance assay,
human APOBEC3H was shown to cause ~6.1-fold increase in mutation frequency, while
macaque APOBEC3H caused a ~3.1-fold increase over background. By sequencing the
rpoB gene, a significant increase of G to A mutations was detected, confirming both
human and macaque APOBEC3H are proficient in deaminating cytosines in DNA. In
contrast, mammalian cells overexpressing human APOBEC3H were used to obtain HIV-1
proviruses, the viral genome did not carry any detectable G to A mutations; however a
significant hypermutation was observed in viral genomes obtained from cells expressing
macaque APOBEC3H and human APOBEC3G [48].
The weak HIV-1 restriction potential of human APOBEC3H was attributed to its
poor expression in primate cells, although it is an active deaminase. Evidence for its
potential to mutate the genome of DNA viruses, such as HBV [31] and HPV [21] suggest
that human APOBEC3H is active in mammalian cells. In order to investigate the
underlying cause for the reduced HIV-1 restriction potential and poor expression of human
APOBEC3H in cell culture, Dang Y. et a.l [52] compared the amino acid sequences of
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several primate APOBEC3H enzymes. Macaque APOBEC3H is 210 amino acids long.
The presence of a premature termination codon in the last (fifth) exon in both human and
chimpanzee APOBEC3H results in a truncated version in these organisms [52]. The
premature termination codon in human APOBEC3H causes a 29 amino acid deletion from
the C-terminal end. Loss of these amino acids was attributed to the significantly lower
levels of this protein in cells [52]. This deletion was not seen in APOBEC3H genes of
macaque and African green monkey. The mRNA level of this shortened APOBEC3H was
reduced drastically even though the protein stability was unaffected [52]. Interestingly,
restoration of the truncation by repairing the termination codon or increasing the
expression of APOBEC3H under the control of a strong promoter, showed increased
protein expression. The restored or optimally expressed APOBEC3H showed potent anti
HIV-1 and SIV restriction potential [52]. In addition, the authors propose that HIV-1 vif was
capable of counteracting the restriction, only when APOBEC3H was expressed well. The
barely detectable levels of G to A hypermutations in the HIV-1 genome suggests that
although human APOBEC3H is capable of restricting HIV-1, the mechanism is
deamination independent. [52].
To further investigate the reasons for the loss of anti-retroviral activity of human
APOBEC3H, OhAinle M. et al. [51] analyzed the evolution of the activity of hominoid
APOBEC3H enzymes. The reconstructed ancestral human APOBEC3H sequence, which
showed potent antiretroviral activity, was lost due to two independent polymorphisms that
destabilized the protein [51]. The amino acid mutations R105G or ΔN15 contributed to
decrease the half life of the protein. Although the majority of the human population
showed a reduced amount of stable APOBEC3H expression, hence no antiretroviral
activity, individuals of African descent stably express APOBEC3H. Cells from African
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populations are capable of inhibiting HIV-1 and LINE-1 retrotransposition [51]. Similar to
the ancestral APOBEC3H, this allele does not contain the destabilizing mutations and is
sensitive to HIV-1 vif. This suggests that the evolution of human APOBEC3H is under
strong negative correlation with its potential to restrict retroviruses, presumably because
of the evolution of many other retroviral restriction factors in human cells or more
functionally proficient APOBEC3 enzymes. As explained below, the population specific
variation in the stability of human APOBEC3H is identified due to the presence of multiple
substitution mutations in the gene in different human lineages.
Interestingly, multiple polymorphisms exist naturally in human APOBEC3H.
Primarily, the G105R, K121E and E178D cluster of substitution mutations are observed in
African populations frequently, but are considerably less common in Asian and European
populations [53]. This cluster, not the wild type, has shown restriction potential against
HIV-1, Alu and non-LTR LINE-1 retrotransposition [54].

The observation that this

APOBEC3H variant expresses well in mammalian cells compared to wild type was
attributed to its highest potential in HIV-1 restriction. In short, the variants of APOBEC3H
show different levels of restricting retroviruses and retrotranpositions. Harari et al.
continued to study the polymorphisms that exist in the human APOBEC3H population and
found that more APOBEC3H variants exist in the human population [53].
As explained below, several groups have also provided evidence for the existence
of multiple APOBEC3H variants in human tissues and cells. Additionally, the degree of
antiretroviral activity against HIV-1 and resistance to vif is assessed in several findings.
Harari et al. [53] studied APOBEC3H cDNA obtained from peripheral blood
mononuclear cells (PBMC) of twelve HIV-1 negative healthy blood donors. Four different
APOBEC3H genetic variants were identified in these donors. HapI-GKE served as the
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wild type reference sequence, (NM_181773) where G, K and E are the amino acids at
positions at 105, 121 and 178 in human APOBEC3H. The nonsynonymous substitution
mutations at amino acid positions at this positions; G105R, K121D and E178D produce
the second haplotype of human APOBEC3H, denoted HapII - RDD. Moreover, two
additional haplotypes were identified in these cells [53]. Hap II - RDD with Δ15N is
denoted as haplotype III. Hap II - RDD with Δ15N and L18R is denoted as haplotype IV.
The four major haplotypes are expressed in a population dependent manner. Additional
APOBEC3H genetic variants are listed in the Single Nucleotide Polymorphism database
at NCBI. (www.ncbi.nlm.nih.gov/projects/SNP). These are one synonymous substitution
mutation at codon 43, two deletions (Δ14 and Δ15) and several nonsynonymous
mutations (R18L, G37H, G105R, K121E/N, S140G, and E178D). Haplotype I was the
most abundant variant of APOBEC3H as it was present in 10 out of 12 blood donors [53].
The alternative splicing of human genes plays an important role in the functions of
the gene products leading to diverse and varying enzyme amounts and activities in cells.
In addition, the expression profiles and the levels of the splice variants may differ, in a cell
or tissue specific manner. Sometimes the expression profile reflects the function of the
variant [55]. In addition to the human APOBEC3H haplotypes, four different splice variants
were found in the human blood cells, namely sv-154, sv-182, sv-183 and sv-200 [53]. The
numbers denote the length of the proteins in amino acids.

13

Figure 4: Representation of the four major splice variants of human APOBEC3H.
CDD: cytosine deaminase domain.

All the splice variants share exons 2, 3 and 4, except sv-154, which has skipped
exon 4 but contains the cryptic exon 4b. In addition to exon 4, sv-200 has the cryptic exon
4b. sv-182 is devoid of the glutamine in exon 5, that is found in sv-183 (Figure 4). The four
splice variants are comprised of SNPs that are described above. From the genomic
sequences of the transcript variants, it can be concluded that human APOBEC3H is highly
diverse and contains multiple haplotypes and splice variants that have distinct C-terminal
domains. Harari et al. [53] compared the potential of inhibiting HIV-1 by all the variants of
human APOBEC3H. They observed that the splice variants of hapII-RDD was more
powerful and uniform in restricting HIV-1 than hapI-GKE, as the splice variants of hapIGKE showed varying levels of antiretroviral ability. But, the sv-183 of hapI-GKE showed
20-fold more restriction potential than background, which was the level of restriction
observed by APOBEC3G. This result suggests that sv-183 of HapI-GKE has greater
potential in restricting HIV-1 replication in mammalian cells [53].
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Figure 5: Human APOBEC3H splice variants from ENSEMBL genome browser

Figure 6: Four splice variants of human APOBEC3H found in PBMCs
(sv-183, sv-182, sv-200 and sv-154). They contain distinct C-terminal domains
The CDD is underlined. In purple, the unique C-terminal domains are indicated.
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Although APOBEC3H is distinct from other APOBEC enzymes in humans, it
closely resembles the CTD of mouse APOBEC3 [9]. Mouse APOBEC3 is sensitive to HIV1 vif and the restriction potential of mouse APOBEC3 against HIV-1 is comparable to that
of human APOBEC3G [53]. Harari et al. [53] and several other groups [56, 57] have
confirmed that human APOBEC3H is also HIV-1 vif resistant. To study the underlying
mechanism of the resistance to HIV-1 vif by human APOBEC3H, Li et al. [57] compared
the level of susceptibility of APOBEC3H to several vif proteins cloned from HIV-1 infected
patients with different APOBEC3H genotypes. The SNP K121D in hap-II has been
identified as the major determinant for conferring resistance against HIV-1 vif, as hapIIRDD has increased antiretroviral activity against HIV-1, consistent with previous studies
[53, 57]. Interestingly, change of lysine at position 121 to an acidic amino acid increased
susceptibility to HIV-1 vif. Using novel antibodies to detect untagged human APOBEC3H,
instead of identifying tagged versions, they observed that the hap-I conferred low
resistance to HIV-1, as did splice variants of hap-III and hap-IV [57]. Consistent with
previous studies, hap-II was highly expressed than the other variants, and showed
increased potential in restricting vif deficient HIV-1. In contrast to the previous studies, by
directly comparing protein levels with and without HIV-1 vif, Zhen et al. [56] proposed that
hap-II is susceptible to HIV-1 vif, although hap-I is completely resistant to proteasomal
degradation. Studying a panel of vif mutants, they suggested that, apart from the motifs in
vif that are involved in interacting with APOBEC3G and APOBEC3F, additional motifs of
vif were identified in interacting with APOBEC3H hap-II. After obtaining similar expression
levels for both hap-I and hap-II, Zhen et al. [56] observed that both the variants had similar
virion packaging levels and antiretroviral activity against HIV-1. As the mutant hap-I
G105R was more stable than the hap-I variant, and showed increased steady state
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protein levels, it can be concluded that residue 105 is critical for the stability of the protein
[56]. Introduction of this positively charged residue at this position might increase its
solubility or provide a suitable interaction surface for an accessory factor that increases its
stability as this residue is exposed to the surface (From modeling with APOBEC3G-NTD
and APOBEC2 structure).
Ooms et al. [58] proposed a different phenomenon to explain the varying levels of
antiretroviral activity between hap-I and hap-II. The localization of the APOBEC3H
variants within the egressing HIV-1 virion was considered as the vital factor, not protein
expression levels. Hap-II RDD interacted with the nucleocapsid part of the Gag protein in
the virion, in an RNA dependent manner; whereas hap-I GKE interacted with the Cterminal of the capsid. The high affinity of the hap-II variant to host RNA resembles
APOBEC3G, as APOBEC3G is incorporated to the virion in an RNA dependent manner.
As hap-II RDD is proficient in restricting HIV-1, its ability to interact with the nucleocapsid
part of the Gag protein was considered to be the major determinant. In contrast, hap-I did
not show any RNA binding or HIV-1 restriction [59]. The W115 residue of hap-II RDD was
crucial for the RNA binding ability [59]. The deletion of N15 in hap-III and hap-IV is
implicated in its reduced affinity to RNA. Using a rifampicin resistance assay, Ooms et al.
[58] observed that the APOBEC3H variants have comparable DNA cytosine deaminase
activities, but the activity correlated with the expression in E. coli.
Wang et al. [60] in 2011 identified three novel SNPs in six different human
populations, in addition to the N15Δ, R18L, G105R, K121D and E178D, discussed above.
The new polymorphisms are named hap-V (N15, R18, R105, D121, E178), hap-VI (N15Δ,
L18, G105, K121, D178) and hap-VII (N15, R18, R105, K121, E178). Hap-V and VII
expressed high levels of proteins in the steady state and restricted HIV-1 replication. From
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the studies on hap-VII, the motif, YYXW (residues 112-115) was identified to be critical for
the interaction with the HIV-1 nucleocapsid, hence virion packaging. The Y112A mutation
completely abolished the incorporation of APOBEC3H into HIV-1 virions. Replacement of
the corresponding region of APOBEC3H with the motif crucial for the vif interaction from
APOBEC3G did not increase the vif sensitivity of APOBEC3H [60].
Li et a.l [61] discovered that human APOBEC3H hap-II prefers cytoplasmic localization,
similar to macaque APOBEC3H, whereas hap-I is primarily retained in the nucleus. The
exclusive localization of hap-II in the cytoplasm is attributed to its interaction with host
factors that are necessary for HIV-1 restriction. As retroviral reverse transcription occurs in
the cytoplasm, the APOBEC3 enzymes must be located there to do this job. Hap-I GKE is
translocated to the nucleus by passive diffusion. The putative NES at the C-terminal of the
ancestral primate APOBEC3H has been lost due to mutations [61]. Truncation of the C
terminal region of the NES in humans and chimpanzee APOBEC3H was observed later in
evolution, leading to increased nuclear localization of the APOBEC3H variants, and
reducing antiretroviral activity. The single mutation G105R was sufficient to change from
nuclear to cytoplasmic localization for hap-I GKE [61]. A summary of antiviral activity, vif
sensitivity, and the distribution profiles of the human APOBEC3H haplotypes and its splice
variants are shown in Table 1.
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APOBEC3H
haplotypes/

Antiviral activity

Vif sensitivity

Remarks

splice variants
Ancestral

human Restrict HIV-1, LINE-1, Sensitive to HIV-1 African

APOBEC3H

Alu [51]

vif [51]

populations

Inhibit non-LTR LINE-1

All

[54], Alu[54]

resistant to HIV-1 Africans [57, 60]

(G105R, N15)
hapII-RDD

variants Prevalent

retrotransposition, strong vif [53], completely
HIV-1 restriction [53, 56-

sensitive to HIV-1

58, 62]

vif [56]

hap I –GKE sv- WT
183

HIV-1

restriction HIV-1 vif resistant

comparable

to [53, 57], sensitive

APOBEC3G [53], weak to HIV-2 vif [57]
anti HIV-1 activity [57,
58]
hap
183

II-RDD

sv- WT

HIV-1

restriction HIV-1 vif resistant

higher than APOBEC3G [53],

Somewhat

[53], powerful anti HIV-1 sensitive to HIV-1
Δvif activity [57, 61]

vif [57], sensitive
to HIV-2 vif [57]

hap I –GKE sv- Poor restriction of HIV-1
182

than hap I –GKE sv-183
[53]

in
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APOBEC3H
haplotypes/

Antiviral activity

Vif sensitivity

Remarks

splice variants
hap I –GKE sv- Poor restriction of HIV-1
200

than hap I –GKE sv-183
[53]

hap II –RDD sv- Higher restriction of HIV182

1 than hap II- RDD sv183 [53]

hap II –RDD sv- Higher restriction of HIV- HIV-1 vif resistant
200

1 than hap II- RDD sv- [53]
183

(comparable

to

APOBEC3G) [53]
hap - III sv-183

No HIV-1 restriction [57]

hap – IV sv-183

No HIV-1 restriction [57]

hap – V sv-183

Restrict HIV-1[60]

AfricanAmerican,
Chinese
populations[60]

hap – VII sv-183

Restrict HIV-1[60]

European
Caucasian[60]

Table 1: Summary of activity and distribution of human APOBEC3H
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Despite biological functions such as retroviral restriction and inhibition of
retrotransposition, the biochemical properties and the enzyme kinetics of human
APOBEC3H are currently unknown. Also a high resolution crystal or NMR structure with
or without DNA substrate bound is not yet available for any of the variants of human
APOBEC3H. In order to obtain biochemically valid kinetic parameters, homogeneous
preparation of the active form of the enzyme is required. The question of structure-activity
relationships in various haplotypes can be addressed from a valid crystal or NMR
structure. In addition, the residues that are important for interactions with HIV-1 vif in
different variants can also be determined by suitable crystal structures with vif. Finally,
homogeneous preparations of human APOBEC3H protein variants are crucial for
analyzing and confirming the activity profile observed in biological studies.
In the Ensembl Genome Browser (accessed March 2014), four protein coding
human APOBEC3H variants are found. The gene identity is ENSG00000100298. For this
study, I used two hapI-GKE splice variants that encode 200 and 183 amino acid proteins.
The DNA cytosine deaminase activity was compared between the two variants using both
an E. coli based genetic reversion assay and an in vitro DNA cytosine deamination activity
assay which was carried out using purified APOBEC3H.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Cloning of human APOBEC3H
A cDNA clone of human APOBEC3H hapI-GKE sv-200 (NCBI sequence
NM_001166003) was purchased from OriGene Technologies (Rockville, MD) and used as
the template for cloning. All the clones that were generated were validated by sequencing.
(The DNA Sequencing Core, University of Michigan, Ann Arbor). Plasmid extractions on a
small scale were done using an E.Z.N.A.® Plasmid Mini Kit I (Omega Bio-Tek, Norcross,
GA).
The cDNA were cloned into the pACYC184-based expression plasmid pSU24 [63]
to carry out the kanamycin resistance reversion assay (Figure 7). To clone the splice
variant with 200 amino acids, the cDNA was amplified using the primers, pSUA3H200-F
and pSUA3H200-R to introduce 5′ HindIII and 3’ EcoRI sites. To clone, APOBEC3H-183,
the same template cDNA was used but was amplified with pSUA3H183-F and
pSUA3H183-R and the same restriction sites were introduced. The resulting clones were
named as pSUA3H-200 and pSUA3H-183, respectively.
To purify the APOBEC3H-200 protein, an N-terminally GST tagged version was
cloned (Figure 8). The cDNA for APOBEC3H hap I GKE sv-200 was cloned into pGEX4T3
vector (GE Healthcare) as 5’ EcoRI and 3’ XhoI sites and named pGA3H200.
To purify the APOBEC3H-183 protein, an N-terminally poly-histidine tagged
version was generated (Figure 9). The cDNA for APOBEC3H hap I GKE sv-200 was used
as template and amplified cDNA of sv-183. cDNA was cloned into pET28a+ vector
(Novagen) as 5’ NdeI and 3’ XhoI sites and named pETA3H183.
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The primers used for cloning were custom synthesized by Sigma-Aldrich
(Woodlands, TX). The sequences of the primers are listed in Table 2.

Name of the
oligonucleotide

Sequence

pSUA3H200-F

5’ GCG GCG GCG AAG CTT ATG GCT CTG TTA ACA GCC

pSUA3H200-R

5’ GCG GCG GCG GAA TTC TCA TCA GAC CTC AGC ATC

pSUA3H183-F

5’ GCG GCG GCG AAG CTT ATG GCT CTG TTA ACA GCC

pSUA3H183-R

5’ GCG GCG GCG GAA TTC TCA TCA GGA CTG CTT TAT CCT

pETA3H183-F

5’ GGC CGC CCA TAT GGC TCT GTT AAC AG

pETA3H183-R

5’ GCG CGC GGA ATT CTC ATC AGG ACT GCT TTA TCC TCT C

GSTA3H200-F

5’ GGG CCC GGG GAA TTC CGC TCT GTT AAC AGC CG

GSTA3H200-R

5’ GGG CCC GGG CTC GAG TCA GAC CTC AGC ATC ACA

CCC

(6-FAM) 5' ATT ATT ACC CAT TTA TT

CCU

(6-FAM) 5' ATT ATT ACC UAT TTA TT

ACC

(6-FAM) 5' ATT ATT AAC CAT TTA TT

TCC

(6-FAM) 5' ATT ATT ATC CAT TTA TT

GCC

(6-FAM) 5' ATT ATT AGC CAT TTA TT

Table 2: The oligonucleotide sequences.
6-FAM: 6-carboxyfluorescein
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Figure 7: pSU24 plasmid map and MCS.
APOBEC3H splice variants were introduced as HindIII and EcoRI fragments.

Figure 8: pGEX4T3 plasmid map and MCS.
APOBEC3H-200 was introduced as an EcoRI and XhoI fragment.
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Figure 9: pET28a+ plasmid map and MCS.
APOBEC3H-183 was introduced as an NdeI and XhoI fragment.

2.2 Purification of GST-APOBEC2H-200
The plasmid pGA3H200 was transformed into the E. coli strain BL21. Ten to
twelve single colonies were inoculated into a single 5 mL of Luria Bertani (LB) medium
culture containing 50 μg/mL carbenicillin, which was grown overnight at 37 °C. A 1:1000
dilution was performed from the overnight culture into 500 mL LB with carbenicillin. The
cells expressing the protein were grown to mid-log phase with adequate aeration at 37 °C.
The culture was cooled to 4 °C and expression was induced by adding IPTG (Gold
Biotechnology) at a final concentration of 0.2 mM. The culture was grown overnight at 16
°C with shaking. Cells were spun down using a Sorvall rotor at 8,000 rpm for 20 minutes
at 4 °C. The cells were lysed using a French pressure cell press (Thermo Spectronic) in
30 mL of 20 mM Tris-HCl, pH 8.0 and 50 mM NaCl containing a half a tablet of an EDTA
free protease inhibitor cocktail. (Roche diagnostics, Indianapolis. IN). The lysate was
clarified by centrifuging at 14,000 rpm for 20 minutes at 4 °C. The cleared lysate was
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incubated with glutathione sepharose 4B beads (GE Healthcare) in a total column volume
of 750 μL for 2 hours at 4 °C on a rotating platform. The lysate was allowed to settle and
the flow through was collected. The beads were washed with 10 column volumes of buffer
containing 20 mM Tris-HCl, pH 8.0 and 50 mM NaCl. The protein was eluted using buffer
containing 50 mM Tris-HCl, pH 8.0 and 20 mM reduced glutathione (Sigma Aldrich); 1 mL
fractions were collected. The cell free lysate (15 μL each), flow through, wash fractions
and elution fractions were mixed with SDS-PAGE gel loading buffer (50 mM Tris-HCl, pH
6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue and 10 % glycerol). The samples
were heated at 95 °C for 5 minutes and briefly spun down. The soluble portion was loaded
onto a 12% SDS-PAGE gel and ran at 100 V in 20mM Tris-HCl, 192 mM glycine and 0.1%
SDS buffer. The gel was stained in Coomassie Brilliant Blue (BioRad) (1g/L), 50%
methanol and 10% glacial acetic acid. The gel was destained using 50% methanol and
10% glacial acetic acid. The fractions that contained the desired protein (expected size of
GST-A3H200 is ~48 kDa) were dialyzed using 10 kDa molecular weight cut-off Slide-ALyzer Dialysis Cassettes (Thermoscientific, Rockford, IL) in 20 mM Tris-HCl, pH 7.6, 50
mM NaCl, 1 mM EDTA, 1 mM DTT and 10% glycerol at 4 °C overnight. The resultant
protein preparation was concentrated using a 10 kDa molecular weight cut-off Amicon
Ultra Centrifugal device (Milipore, Billerica, MA) by centrifuging at 4,000 g for 20-30
minutes at 4 °C. The concentration of the final protein preparation was measured using
Bradford reagent (Bio-Rad) against BSA standards from the absorption at 595 nm. Protein
was aliquoted and stored at -20 °C until further use. For initial activity assays, 1 μg of the
protein was used in each reaction.
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2.3 Western Blotting of GSTA3H200
To confirm the overexpression of GSTA3H200 in BL21 cells, a Western blot was
carried out on the concentrated eluate obtained from the glutathione affinity column.
Briefly, 20 μL of the elution fraction was mixed with of SDS-PAGE gel loading buffer (50
mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromophenol blue and 10 % glycerol).
The content was mixed and heated at 95 °C for 5 minutes and briefly spun down. An
aliquot of the soluble portion (15 μL) was loaded onto a 12% SDS-PAGE gel and ran at
100V in 20 mM Tris-HCl, 192 mM glycine and 0.1% SDS.
The proteins were electrophoretically transferred to a PVDF membrane (EMD
Millipore) which had been presoaked in methanol. The transfer was carried out at 100 mA
for two hours at 4 °C. The blot was incubated with the blocking buffer, 5% non-fat dry milk
in 1X TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20) at 4 °C overnight.
The blot was washed for 5 minutes three times with TBS-T and incubated with the rabbit
anti-GST tag primary antibody (GeneScript) with a final concentration of 1 μg/mL at room
temperature for two hours. The blot was washed again with TBS-T and was incubated
with the secondary antibody, goat anti-rabbit antibody (AnaSpec) with a final
concentration of 1 μg/mL at room temperature for one hour. The blot was washed again
with TBS-T and scanned using Typhoon Phosphorimager (GE Healthcare) at the
excitation wavelength of 633 nm under a red laser.
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2.4 Kanamycin resistance reversion assay
The E. coli based genetic assay was described before [64, 65]. Briefly, a defective
kanamycin allele was used; in which 94th leucine residue was mutated to proline
(kanamycin sensitive phenotype in E. coli).

After one round of replication, the

deamination of cytosines to uracils in this codon will result in C to T mutations, restoring
the kanamycin resistant phenotype. The number of C to T mutations is scored as the
kanamycin resistance revertant frequency (Figure 10). Plasmids, pSUA3H-200 or
pSUA3H-183 was cotransformed with the pUP31 plasmid into BH214 strain of E. coli
which is a GM31 ung mug strain. The defective kanamycin allele is provided from pUP31
[66, 67]. For the positive control, human APOBEC3A cloned into pSU24 (pSUA3A) was
used [26]. The empty vector, pSU24, or the catalytically null mutant of human APOBEC3A
cloned in pSU24 (pSUA3AE72A) [26] were used as negative controls. The
cotransformants were selected by plating on an LB plate containing chloramphenicol (25
μg/mL) and carbenicillin (50 μg/mL). LB medium (5 mL) with chloramphenicol (25 μg/mL)
and carbenicillin (50 μg/mL) was inoculated with a single colony from the selective plate.
The culture was grown overnight. A 1:1000 dilution of the overnight culture was carried
out in LB containing the appropriate antibiotics and the culture was grown for two hours at
37 °C with shaking. For the experiments with IPTG induction, varying concentrations of
IPTG were added to the cultures. The cultures were split into eight or more independent
cultures (5 mL each). The cultures were grown until the mid-log phase (i.e. OD600 ~ 0.4 to
0.6). The cultures were spread onto LB-agar plates with 50 μg/mL kanamycin to score the
number of revertants. To score for the total number of viable cells, a 2.5 x 106 dilution of
the cultures were plated on LB-agar plates containing 25 μg/mL carbenicillin. Kanamycinresistance revertant frequency was calculated as the ratio between the numbers of
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kanamycin-resistant colonies to the total number of viable cells. The median values were
calculated and analyzed using GraphPad Prism software. The Mann-Whitney t-test was
used to calculate p-values.

Figure 10: The basis of the kanamycin resistance reversion assay.

2.5 Purification of poly-histidine tagged A3H-183 using nickel affinity
The plasmid pETA3H183 was transformed into the E. coli strain BL21 (DE3). Ten
to twelve single colonies were inoculated into a single 5 mL of LB medium culture
containing 50 μg/mL kanamycin, which was grown overnight at 37 °C. A 1:1000 dilution
was performed from the overnight culture into 500 mL LB with kanamycin. The cells
expressing the protein were grown to mid-log phase with adequate aeration at 37 °C. The
culture was cooled to 4 °C and expression was induced by adding IPTG (Gold
Biotechnology) at a final concentration of 0.2 mM. The culture was grown overnight at 16
°C with shaking. Cells were spun down using a Sorvall rotor at 8,000 rpm for 20 minutes
at 4 °C. The cells were lysed using French pressure cell press (Thermo Spectronic) in 30
mL of 20mM Tris-HCl pH 8.0, 50mM NaCl and 40mM imidazole (Sigma-Aldrich)
containing a half a tablet of the EDTA free protease inhibitor cocktail. (Roche diagnostics,
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Indianapolis. IN). The lysate was clarified by centrifuging at 14,000 rpm for 20 minutes.
The cleared lysate was incubated with high affinity Ni-charged resin (GenScript) in a total
column volume of 1 mL for one hour at 4 °C on a rotating platform. The lysate was
allowed to settle and the flow through was collected. The beads were washed with 10-15
column volumes of the buffer containing 20 mM Tris-HCl, pH 8.0, 40 mM imidazole and 50
mM NaCl (wash 1). Wash was repeated with 20 mM Tris-HCl, pH 8.0, 40 mM imidazole
with increasing NaCl concentrations (200 mM and 500 mM respectively) with each step.
The wash steps were carried out until no detectable proteins were eluted in Bradford
qualitative assay. These wash steps are indicated as wash 2 and 3 in Figure 16. The
protein was eluted in 20 mM Tris-HCl, pH 8.0, 500 mM NaCl with 300 mM imidazole. 15
μL of the cell free lysate, flow through, wash and elution fractions were mixed with SDSPAGE gel loading buffer. The samples were heated at 95 °C for 5 minutes and briefly
spun down. The soluble portion was loaded onto a 15% SDS-PAGE gel and ran at 100V
in 20mM Tris-HCl, 192 mM glycine and 0.1% SDS buffer. The gel was stained in
Coomassie Brilliant Blue (BioRad) (1g/L), 50% methanol and 10% glacial acetic acid. The
gel was destained using 50% methanol and 10% glacial acetic acid. The fractions that
contained the desired protein (expected size of His-A3H183 is ~23 kDa) were dialyzed
using 10 kDa molecular weight cut-off Slide-A-Lyzer Dialysis Cassettes (Thermoscientific,
Rockford, IL) in a step-wise manner. First, the dialysis was carried out in 20 mM Tris-HCl,
pH 7.6, 200 mM NaCl, 1mM EDTA, 1mM DTT and 10% glycerol at 4 °C for 8-10 hours
and it was repeated for another 8 hours, with the same buffer, except with a NaCl
concentration of 50 mM. The resultant protein preparation was concentrated using 10 kDa
molecular weight cut-off Amicon Ultra Centrifugal device (Milipore, Billerica, MA) by
centrifuging at 4000 g for 20-30 minutes at 4 °C. The concentration of the final protein

30

preparation was measured using Bradford reagent against a standard series of BSA from
the absorption at 595 nm. The protein was aliquoted and stored at -20 °C until further use.
For initial activity assays, 1 μg of the protein was used in each reaction.

2.6 Western Blotting of his-A3H183
To confirm the overexpression of N-terminally poly-histidine tagged APOBEC3H183 in BL21(DE3) cells, a Western blot was carried out with the eluate and other fractions
obtained from nickel affinity purification. Briefly, 17μL of the cell free lysate, flow-through,
portions from the wash steps, and elution fractions were each mixed with SDS-PAGE gel
loading buffer. The samples were mixed and heated at 95 °C for 5 minutes and briefly
spun down. Aliquots of the soluble portion (15 μL) were loaded onto a 15% SDS-PAGE
gel and ran at 100V in 20 mM Tris-HCl, 192 mM glycine and 0.1% SDS.
The proteins were electrophoretically transferred the proteins to a PVDF
membrane (EMD Millipore) which has been presoaked in methanol. The transfer was
carried out at 100 mA for two hours at 4 °C. The blot was incubated with the blocking
buffer, 1% BSA in 1X TBS-T (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20) at
room temperature overnight. The blot was washed for 5 minutes three times with TBS-T
and incubated with the mouse anti-his tag primary antibody (AnaSpec) with a final
concentration of 1 μg/mL at room temperature for two hours. The blot was washed again
with TBS-T and was incubated with the secondary antibody, goat anti-mouse IgG (H+L),
Hilyte FlourTM 647-labeled (AnaSpec) with a final concentration of 1 μg/mL at room
temperature for one hour. The blot was washed again with TBS-T and scanned using a
Typhoon Phosphorimager (GE Healthcare) at the excitation wavelength of 633 nm under
a red laser.
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2.7 Size exclusion chromatography of poly-histidine tagged A3H-183
A fresh preparation of overexpressed lysate was obtained from a 2 L culture, as
described above in section 2.5. All growth and purification conditions were scaled-up
accordingly. As the protein was active under the elution condition that was used in nickel
affinity purification, the buffer containing 20 mM Tris-HCl, pH 8.0 and 500 mM NaCl was
used to equilibrate the column. A total of ~0.8 mg of crude eluate from the nickel affinity
column was used to load a HiLoad 16/600 Superdex 200 pg (GE Healthcare) size
exclusion column. Fractions (2 mL) were collected at a flow rate of 0.5 mL per minute. The
fractions containing the refined protein were pooled and a total of 10 μL was loaded onto
a 15% SDS-PAGE gel. Fractions containing the higher molecular weight contaminant
were also processed as above and 10 μL was loaded onto the gel. After confirming the
presence of the desired protein at the proper void volume, without the high molecular
weight contaminant, the pooled fractions were concentrated using a 10 kDa molecular
weight cut-off Amicon Ultra Centrifugal device, (Milipore, Billerica, MA) by centrifuging at
4,000 g for 20-30 minutes at 4 °C. The two step dialysis was carried out as described in
section 2.5. The high molecular weight contaminant was removed from the size exclusion
column. The resultant pure protein was used to carry out further activity assays.

2.8 In vitro activity assays of purified APOBEC3H proteins
To complement the genetic data obtained from the kanamycin resistance reversion
assay, the partially purified GSTA3H200 and poly-histidine tagged A3H-183 (HisA3H183)
was tested for their ability to deaminate cytosine in vitro. Essentially pure hisA3H183
obtained from the size exclusion column was also tested. Four different 17-mers of DNA
were used in the assay. The oligonucleotides were 5’ 6-FAM labeled and contains two
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consecutive cytosines preceded by either A, G, T or C. The oligonucleotide used for a
positive control contained ‘CCU’ sequence. All the oligonucletides were custom
synthesized from Integrated DNA Technologies (San Jose, CA) and were PAGE purified
prior to use. The sequences of the oligonucleotides are listed in Table 2. Briefly, 1 pmol of
oligonucleotide was incubated with partially purified GSTA3H200 or hisA3H183 and
incubated for two hours at 37 °C. The total reaction volume was 10 μL in the reaction
buffer containing 40 mM Tris-HCl, pH 7.4, 5 mM EDTA, 1 mM DTT and 40 mM NaCl. One
unit of E. coli UDG (New England Biolabs, Ipswich, MA) was added with the UDG reaction
buffer (20 mM Tris-HCl, pH 8, 1 mM EDTA, 1 mM DTT) and the reaction was continued at
37 °C for one hour. NaOH was added to a final concentration of 0.1 M and the reaction
was heated for 5 minutes at 95 °C. An equal volume of formamide containing gel loading
dye (95% formamide, 0.025% bromophenol blue, 5 mM EDTA) was added to the reaction
mixture and the mixture was heated again for 5 minutes at 95 °C. The reaction was briefly
spun down at 10,000 g for one minute and 10 μL was loaded onto a denaturing 20%
DNA-PAGE gel. The gel was run in 1X TBE buffer at 90 V. The gel was scanned using
Typhoon 9210 phosphorimager (GE Healthcare) with an excitation wavelength of 499 nm.
The intensities of the substrates and the products were quantified using ImageQuant
software. Percent conversion of the substrate was calculated per the equation: (intensity
of the product band - intensity of the background) / ((intensity of the substrate band intensity of the background) + (intensity of the product band - intensity of the
background)). For the homogenous protein preparation of hisA3H183 obtained from size
exclusion, different amounts were used for the activity assays. The assays were carried
out as described above.
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CHAPTER 3: RESULTS AND DISCUSSION
The main objective of this project was to obtain a version of human APOBEC3H
that is active, both in vivo and in vitro. To study the DNA cytosine deaminase activity, I
used a novel E. coli mutator assay, the kanamycin resistance reversion assay.
The kanamycin resistance reversion assay data for the 200 amino acid version of
APOBEC3H (Figure 11) suggests that the APOBEC3H-200 is not an efficient DNA
cytosine deaminase. Eight to twelve independent cultures were used to determine the
median value of the kanamycin resistance reversion frequency of each population,
including the negative control (empty vector). The median value of the kanamycin
resistance reversion frequency of the splice variant APOBEC3H-200 was only ~3 fold
(p=0.052) higher than the empty vector control.

Figure 11: Kanamycin resistance reversion assay results for pSUA3H-200.
The median value of the revertant frequency is shown by the horizontal bar.
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To assess the in vitro biochemical activity, an N-terminally GST tagged version of
A3H200 was obtained using glutathione affinity chromatography. Figure 12 represents the
12% SDS PAGE gel with the protein fractions that were collected.

Figure 12: 12% SDS-PAGE gel for GSTA3H200 purification.
Lane 1 : Molecular weight marker, Lane 2 : CFL, Lane 3 : Flow-through,
Lane 4 : wash, Lanes 5-10 : eluates of GSTA3H200 (boxed)
The expected protein size of GSTA3H200 was ~48 kDa, which was not
significantly over-expressed. Thus, a Western blot was carried out using anti-GST mouse
primary antibody. As presented in Figure 12, the protein seems to be expressed, with
smaller molecular weight degradation products. The activity assay was performed as
described above using concentrated eluates obtained from the affinity column. A total of
1.5 µg of protein did not give any cleaved DNA product (Figure 14).
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Figure 13: Western blot for GSTA3H200
Lane 1: Molecular weight marker, Lane 2: Eluate from GST affinity column.

Figure 14: DNA cytosine deaminase activity assay for partially purified GSTA3H200

As human APOBEC3H is a known DNA cytosine deaminase, which contains a
conserved zinc binding deaminase domain, we wanted to study the other splice variants
of this enzyme. From a previous study by Harari et al. [53], the splice variant that encodes
183 amino acids (hapI-GKE-183) displayed ~20 fold higher HIV-1 restriction potential than
the other variants. To study the DNA cytosine deaminase efficiency of this splice variant,
the kanamycin resistance reversion assay was carried out using the same conditions as
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above. Interestingly, cells with the human APOBEC3H-183 showed higher kanamycin
resistance revertant frequency than the empty vector control, although the value was not
as high as the human APOBEC3A (Figure 15). Human APOBEC3A cloned in pSU24 has
shown increased DNA cytosine deaminase activity in this assay [26]. The negative control
was a catalytic mutant. APOBEC3AE72A. With increasing concentrations of IPTG, the
revertant frequency was also higher. It is likely that higher IPTG concentrations result in
greater expression of APOBEC3H and hence higher deamination activity. Addition of
IPTG to a final concentration of 100 μM increased the kanamycin resistance reversion
frequency ~10 fold.

Figure 15: Kanamycin resistance reversion assay results for pSUA3H183.
The median value is shown by the horizontal bar.
To complement the genetic data obtained from the E. coli mutator assay, the
activity of the APOBEC3H-183 was tested in vitro using purified proteins. As the first step
in carrying out this in vitro activity assay, APOBEC3H-183 was purified as an N-terminally
poly-histidine tagged APOBEC3H-183 (His-A3H183) using nickel affinity chromatography.
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The SDS-PAGE gel is shown in Figure 16. The crude preparation of protein obtained from
a 500 mL of culture was used to carry out the activity assay.

Figure 16: 15% SDS-PAGE gel for nickel affinity purified APOBEC3H-183.
Lane 1: Molecular weight marker, Lane 2: Flow-through, Lane 3: wash 1, Lane
4: wash 2, Lane 5: wash 3, Lane 6-7: eluate. The expected size of his-A3H-183 (~23 kDa)
is boxed. A higher molecular weight contaminant is indicated by an arrow to the right.
To confirm the overexpression of the poly-histidine tagged A3H183, a Western blot
was carried out using mouse anti-his tag primary antibody. As shown in Figure 17 (lane
9), the correct size of the protein was detected (~23 kDa). This result confirmed that
sufficient protein expression in the soluble fraction of the lysate occurred. Unfortunately, a
significant amount of the protein was lost and cleared through the wash and flow-through
steps, perhaps due to insufficient binding to the nickel beads. This step needs further
optimization.
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Figure 17: Western blot for protein fractions obtained in nickel affinity purification.
Lane 1: Molecular weight marker, Lane 2: Cell-free lysate, Lane 3: flowthough, Lane 4: wash 1, Lane 5: wash 2, Lane 6: wash 3, Lane 7-8: empty, Lane 9:
eluate. The expected protein size of his-APOBEC3H-183 (~23 kDa) is boxed.

We next carried out the in vitro biochemical activity assay using the partially
purified APOBEC3H-183, described in [68] and [69]. Briefly, an event of DNA cytosine
deamination in a single-stranded oligonucleotide will generate uracil. Incubation the
olionucleotide with UDG, excises uracil and generates an abasic site. Treatment with 0.1
M NaOH and heating to 95 °C (hot alkaline treatment), cleaves the phosphodiester
backbone at the abasic site and introduces a single strand break, resulting in a shorter
product. The appearance of this shorter product indicates a positive result or a proficient
DNA cytosine deaminase activity of the enzyme tested. The corresponding 20% DNAPAGE gels are shown in Figures 18 and 19, for assays carried out using the partially
purified N-terminal poly-histidine tagged APOBEC3H. The different reactions in each lane
are indicated. The appearance of two product bands is attributed to the two deamination
events in the consecutive cytosines in the substrate. As seen clearly, the appearance of
the shorter product and the complete or partial disappearance of the substrate,
corresponding to the amount of enzyme, indicates that the enzyme is active under the
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conditions used. The lanes corresponding to the positive and negative controls are
indicated. Although the yield was low, the protein preparation was active and was able to
deaminate the cytosines in the oligonucleotide. The ‘CCC’ and ‘TCC’ substrates (1 pmol
each) were converted 100% to product by 1 µg of the protein. Only ~35% of the substrate
was converted in the ‘ACC’ oligomer. Approximately 65% of the ‘GCC’ substrate was
converted to product under the same conditions. By averaging the four conversions, the
specific activity of the enzyme was calculated to be >0.0125 pmol/µg/min under the
specified conditions, suggesting that the enzyme is active, but has a slow turnover. For
the ‘CCC’ oligo, the specific activity was >0.017 pmol/µg/min.

Figure 18: Biochemical activity assay for partially purified APOBEC3H-183.
‘CCC’ and ‘TCC’ oligomers were used. Lane 1 and lane 2 represent the negative and
positive controls, respectively. The sequences of the substrate oligonucleotides are
indicated in Table 2.
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Figure 19: Biochemical activity assay for partially purified APOBEC3H-183.
‘ACC’ and ‘GCC’ oligomers were used. Lane 1 and lane 2 represent the negative and
positive controls, respectively. The sequences of the substrate oligonucleotides are
indicated in Table 2.

In order to further characterize the structure and the catalytic mechanism of the
human APOBEC3H hap I GKE sv-183, essentially homogeneous preparation of the active
enzyme is required. As the first step, the partially purified protein (his6-A3H-183) was
further refined using size exclusion chromatography. The fractions obtained from the size
exclusion column were concentrated using centrifugal devices and analyzed on a 15%
SDS-PAGE gel. As shown in the chromatogram (Figure 20), the ~100 kDa contaminant
was removed by the size exclusion column. Nearly pure protein was obtained (Figure 21),
even though the yield was poor. Varying amounts of the protein were used to carry out the
in vitro activity assay (Figure 22).
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Figure 20: Size exclusion chromatogram.
The peak corresponding for ~23 kDa is indicated by the arrow.

Figure 21: SDS-PAGE gel (15%) with APOBEC3H-183 from a size exclusion column.
Lane 1: Molecular weight marker, Lane 2: Cell free lysate, Lane 3: Flow-through, Lane 4:
wash 1, Lane 5: wash 2, Lane 6: Eluate from nickel affinity column, Lane 7: concentrated
fractions corresponding to ~23 kDa from the size exclusion column, Lane 9: Higher
molecular weight contaminant from size exclusion column.
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Figure 22 shows the 20% DNA-PAGE gel from the cytosine deaminase activity assay
that was carried out using the fully purified his6-APOBECH-183. Increasing amounts of the
enzyme were used. Only 45 ng of enzyme was able to deaminate ~70% of the substrate.
For 100% activity, >0.1 µg of the protein was sufficient. The amount of enzyme in the
reaction directly correlated to the activity in a 2 hour incubation. The specific activity of the
enzyme is increased to ~0.13 pmol/µg/min.

Figure 22: DNA cytosine deaminase activity assay of his-APOBEC3H-183.
Different amounts of the protein were used in the assay, as indicated.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS
To obtain biochemically valid conclusions and to study structure-activity relationship,
isolation of catalytically active proteins is necessary. Human APOBEC3H is a good
example to study the evolution and positive selection of proteins. As the APOBEC3H
shows human population-specific distribution and several splice variants, further
biochemical characterization of multiple variants are required. In addition, identification of
other cellular partners that interact with this enzyme is crucial for functional analysis. High
resolution crystal and NMR structures of human APOBEC3H have not been obtained. I
have cloned human APOBEC3H hapI-GKE splice variant 183 as an N-terminally polyhistidine tagged version into a pET28 vector and purified it using nickel affinity and size
exclusion chromatography, as the first step in characterizing the biochemical properties of
this enzyme. Purified enzyme was tested for its DNA cytosine deaminase activity. The
protein was efficient in deaminating cytosine in vitro. Further work is required to obtain the
enzymatic parameters, such as catalytic efficiency. In addition, the calatytically-null mutant
of human APOBEC3H, E56A [70] needs to be isolated and tested in vitro. The work in this
project needs to be extended to obtain human APOBEC3H-183 in higher yields to
characterize it biochemically and structurally. The catalytic mechanisms of the variants
can also be evaluated from the structures obtained with suitable DNA substrates.
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The AID/APOBEC enzymes are DNA/RNA cytosine deaminases with important
functions in innate and adaptive immunity. APOBEC3 enzymes play a crucial role in
restricting the replication of exogenous retroviruses such HIV-1 and endogenous
retrotransposition events. In particular, APOBEC3 enzymes have evolved in humans by
gene duplication to compose seven members. APOBEC3H is highly diverse in its allelic
sequence and the distribution is population-specific. It has evolved under strong positive
selection over millions of years. To study the catalytic mechanism, structure, function and
the underlying cause of its high diversity, a high resolution crystal or NMR structure is
required are not yet available. The human APOBEC3H splice variant 183 was purified as
an N-terminally poly-histidine tagged construct and it was tested for biochemical activity
as the first step in characterizing the enzyme.
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